Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

418
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
418
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

528
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
528
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

1.1K
The pathophysiology of pneumonia involves the following steps:
1.1K
Pneumonia IV: Management01:28

Pneumonia IV: Management

511
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
511
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

2.7K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.7K
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

136
Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
136

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

How the Exposome Shapes Our Respiratory Health.

American journal of respiratory and critical care medicine·2026
Same author

Heme orchestrates a tissue stress response to proteolytic damage.

bioRxiv : the preprint server for biology·2026
Same author

Global Variation in Pneumonia Epidemiology.

Clinics in chest medicine·2026
Same author

Host Response Diagnostics in Pneumonia.

Clinics in chest medicine·2026
Same author

Pneumonia Reimagined: Host, Microbe, and the Shifting Landscape of Disease.

Clinics in chest medicine·2026
Same author

Bronchiectasis in Italy: an analysis of the EMBARC registry.

ERJ open research·2026
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Oct 21, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.2K

コミュニティで得られた肺炎

Stefano Aliberti1, Charles S Dela Cruz2, Francesco Amati1

  • 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; IRCCS Humanitas Research Hospital, Respiratory Unit, Rozzano, Italy.

Lancet (London, England)
|September 5, 2021
PubMed
まとめ
この要約は機械生成です。

コミュニティで得られた肺炎 (CAP) は,特に免疫機能が低下した患者で,重大な死亡を引き起こします. 改善された臨床管理戦略は,すべての成人のCAP死亡率と合併症を減らすために不可欠です.

さらに関連する動画

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.1K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.2K

関連する実験動画

Last Updated: Oct 21, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.2K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.1K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.2K

科学分野:

  • 感染症
  • 肺科
  • クリティカル ケア 医療

背景:

  • 地域感染性肺炎 (CAP) は死亡率の大きな原因で,退院後1年以内に患者の3分の1が死亡しています.
  • CAP入院患者の有意な割合 (最大18%) は免疫抑制の危険因子を持っていますが,その特定の管理のための証拠は限られています.
  • CAPの現在の理解と管理プロトコルは,免疫機能低下した個人の独特のニーズをしばしば無視しています.

研究 の 目的:

  • 免疫能力のある人群と免疫不全のある人群の両方に焦点を当てて,コミュニティで得られた肺炎の更新された概要を提供します.
  • CAPに関連する死亡率,罹病率,合併症を減らすために不可欠な臨床管理の特徴を強調する.
  • CAPの管理における将来の臨床的および翻訳的研究分野を特定する.

主な方法:

  • コミュニティで得られた肺炎の管理のための現在の証拠と臨床ガイドラインのレビューと統合.
  • 診断,微生物学的調査,抗生物質療法戦略を含む重要な管理コンポーネントに焦点を当てます.
  • 患者の危険因子,地域流行病学,免疫不全患者の特定のニーズを考慮する.

主要な成果:

  • 効果的なCAP管理には,迅速な診断と微生物学的評価を含む多面的なアプローチが必要です.
  • 患者の危険因子や局所的な耐性パターンを考慮した 経験的および個別化された抗生物質療法が不可欠です
  • 合併症に対処し,抗生物質の移行を最適化し,強力な放出計画とフォローアップを実施することは,改善された結果にとって不可欠です.

結論:

  • コミュニティで得られた肺炎の治療を最適化するには,すべての患者の診断,治療,フォローアップに関する包括的な戦略が必要です.
  • 免疫不全の成人のCAPの管理には,特別の注意と証拠に基づいたガイドラインが緊急に必要とされています.
  • CAPの管理プロトコルを洗練し,患者の生存率と生活の質を改善するために,さらなる臨床的およびトランスレーション研究が不可欠です.